向乙醇酶1通过YWHAZ/帕金轴逆转多发性骨髓瘤中的博特佐米布耐药性

向乙醇酶1通过YWHAZ/帕金轴逆转多发性骨髓瘤中的博特佐米布耐药性

相关实验视频

Updated: Jun 1, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K

Xuejie Gao¹, Qilin Feng², Qikai Zhang¹

¹Department of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.

Journal of biomedical science

|January 19, 2025

概括

酶1 (ENO1) 通过增强线粒细胞衰变和YWHAZ蛋白稳定性,促进多发性髓瘤 (MM) 的进展,从而导致药物耐药性. 抑制ENO1可能会逆转MM患者的博特佐米布耐药性.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物化学生化学

背景情况:

乙诺酶1 (ENO1) 是一种糖解酶,在多发性骨髓瘤 (MM) 中,除了代谢之外,其作用尚不清楚.
了解ENO1在MM病理生理学中的作用对于开发新的治疗策略至关重要.
这项研究调查了ENO1对MM的线粒和博特佐米布诱导的亡的影响.

研究的目的:

阐明恩酶1 (ENO1) 在多发性骨髓瘤 (MM) 发病过程中的作用.
调查ENO1在调节线粒的作用及其对博尔特佐米布诱导的亡的影响.
探索ENO1作为克服MM药物耐药性的潜在治疗标.

主要方法:

对MM患者和健康捐赠者的ENO1表达的比较分析.
在ENO1表达与临床病理特征和结果的相关性分析.
在体内和体外实验包括瘤模型,共免疫沉,西部斑,qPCR,免疫组织化学,流细胞计和细胞功能测试.

主要成果:

ENO1是MM的不良预后因素,抑制瘤发生性,并在敲击时导致细胞循环停止.
通过稳定YWHAZ蛋白质,ENO1促进线粒,对抗其无处不在并增加药物耐药性.
博尔特佐米布和ENO1抑制剂的联合治疗在体外和体内都显示出协同作用的抗MM作用.

结论:

ENO1通过激活线粒细胞衰变并赋予对亡和博特佐米布的抵抗力来驱动MM瘤发生和进展.
通过乙化,ENO1增强了YWHAZ的稳定性,促进了线粒和抑制了博尔特佐米布诱导的细胞死亡.
准ENO1是一个有希望的策略,使MM对博尔特佐米布敏感,并克服耐药性.

关键词:

化学抗药性化学抗药性是一种抗药性.在 ENO1 中, ENO1 是 ENO1 的代码.线粒细胞衰变 - - 线粒细胞衰变 (mitophagy) 是一种多发性骨髓瘤是一种多发性骨髓瘤.这就是为什么YWHAZ.

更多相关视频

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.0K

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K

相关概念视频

02:57

Targeted Cancer Therapies

7.4K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.4K

02:56

Treatment Resistant Cancers

3.2K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

3.2K

Combination Therapies and Personalized Medicine

02:50

Combination Therapies and Personalized Medicine

4.8K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...